Get started
Author

Byungje Sung

Observed name: Byung-Je Sung
ORCID: 0009-0001-1806-2125
Observed ORCID: 0009-0001-1806-2125
OpenAlex ID: A5028172313
An Anti-apoptotic Protein Human Survivin Is a Direct Inhibitor of Caspase-3 and -7
2001 · Sejeong Shin, Byung-Je Sung, et al. · Biochemistry · 681
2.8 Å Resolution Crystal Structure of Human TRAIL, a Cytokine with Selective Antitumor Activity
1999 · Sun-Shin Cha, Min-Sung Kim, et al. · Immunity · 156
PDF
Crystal Structure of TRAIL-DR5 Complex Identifies a Critical Role of the Unique Frame Insertion in Conferring Recognition Specificity
2000 · Sun-Shin Cha, Byung-Je Sung, et al. · Journal of Biological Chemistry · 131
PDF
ABL001, a Bispecific Antibody Targeting VEGF and DLL4, with Chemotherapy, Synergistically Inhibits Tumor Progression in Xenograft Models
2020 · Dong-Hoon Yeom, Yo-Seob Lee, et al. · International Journal of Molecular Sciences · 39
PDF
Grabody B, an IGF1 receptor-based shuttle, mediates efficient delivery of biologics across the blood-brain barrier
2022 · Jung-Won Shin, Sungwon An, et al. · Cell Reports Methods · 33
PDF
A brain-shuttled antibody targeting alpha synuclein aggregates for the treatment of synucleinopathies
2025 · Sungwon An, John J. McInnis, et al. · npj Parkinson s Disease · 23
PDF
N-terminal selective conjugation method widens the therapeutic window of antibody–drug conjugates by improving tolerability and stability
2021 · Min Ji Ko, Daehae Song, et al. · mAbs · 13
PDF
Fc-competent TIGITx4-1BB bispecific antibody exerts potent long-lasting antitumor activity by potentiating CD8 + T cell activity and Fcγ receptor-mediated modulation of the tumor microenvironment
2025 · Wonjun Son, Yangsoon Lee, et al. · Journal for ImmunoTherapy of Cancer · 4
PDF
Abstract 1850: A novel anti-CD137 antibody recognizing the membrane-proximal CD137 domain elicits potent anti-tumor T cell activity in a bispecific antibody format
2021 · Yangsoon Lee, Suyoun Lee, et al. · Cancer Research · 3
Abstract 6524: A novel HER2/4-1BB bispecific antibody, YH32367 (ABL105) shows potent anti-tumor effect through tumor-directed T cell activation
2020 · Moo Young Song, Eun-Jung Lee, et al. · Cancer Research · 2
ABL209 (NEOK002): Designing an EGFR × MUC1 Bispecific TOP1i ADC with Promising Antitumor Activity and Enhanced Therapeutic Window
2026 · Bora Lee, Hyeon Ji Park, et al. · Molecular Cancer Therapeutics · 1
Data from ABL209 (NEOK002): Designing an EGFR × MUC1 Bispecific TOP1i ADC with Promising Antitumor Activity and Enhanced Therapeutic Window
2026 · Bora Lee, Hyeon Ji Park, et al.
Figure 3 from ABL209 (NEOK002): Designing an EGFR × MUC1 Bispecific TOP1i ADC with Promising Antitumor Activity and Enhanced Therapeutic Window
2026 · Bora Lee, Hyeon Ji Park, et al.
Figure S5 from ABL209 (NEOK002): Designing an EGFR × MUC1 Bispecific TOP1i ADC with Promising Antitumor Activity and Enhanced Therapeutic Window
2026 · Bora Lee, Hyeon Ji Park, et al.
Table S3 from ABL209 (NEOK002): Designing an EGFR × MUC1 Bispecific TOP1i ADC with Promising Antitumor Activity and Enhanced Therapeutic Window
2026 · Bora Lee, Hyeon Ji Park, et al.
Table S2 from ABL209 (NEOK002): Designing an EGFR × MUC1 Bispecific TOP1i ADC with Promising Antitumor Activity and Enhanced Therapeutic Window
2026 · Bora Lee, Hyeon Ji Park, et al.
Figure 5 from ABL209 (NEOK002): Designing an EGFR × MUC1 Bispecific TOP1i ADC with Promising Antitumor Activity and Enhanced Therapeutic Window
2026 · Bora Lee, Hyeon Ji Park, et al.
Table S4 from ABL209 (NEOK002): Designing an EGFR × MUC1 Bispecific TOP1i ADC with Promising Antitumor Activity and Enhanced Therapeutic Window
2026 · Bora Lee, Hyeon Ji Park, et al.
Figure 2 from ABL209 (NEOK002): Designing an EGFR × MUC1 Bispecific TOP1i ADC with Promising Antitumor Activity and Enhanced Therapeutic Window
2026 · Bora Lee, Hyeon Ji Park, et al.
Figure S6 from ABL209 (NEOK002): Designing an EGFR × MUC1 Bispecific TOP1i ADC with Promising Antitumor Activity and Enhanced Therapeutic Window
2026 · Bora Lee, Hyeon Ji Park, et al.
Figure 4 from ABL209 (NEOK002): Designing an EGFR × MUC1 Bispecific TOP1i ADC with Promising Antitumor Activity and Enhanced Therapeutic Window
2026 · Bora Lee, Hyeon Ji Park, et al.
Figure S16 from ABL209 (NEOK002): Designing an EGFR × MUC1 Bispecific TOP1i ADC with Promising Antitumor Activity and Enhanced Therapeutic Window
2026 · Bora Lee, Hyeon Ji Park, et al.
Figure S14 from ABL209 (NEOK002): Designing an EGFR × MUC1 Bispecific TOP1i ADC with Promising Antitumor Activity and Enhanced Therapeutic Window
2026 · Bora Lee, Hyeon Ji Park, et al.
Figure S2 from ABL209 (NEOK002): Designing an EGFR × MUC1 Bispecific TOP1i ADC with Promising Antitumor Activity and Enhanced Therapeutic Window
2026 · Bora Lee, Hyeon Ji Park, et al.
Figure 1 from ABL209 (NEOK002): Designing an EGFR × MUC1 Bispecific TOP1i ADC with Promising Antitumor Activity and Enhanced Therapeutic Window
2026 · Bora Lee, Hyeon Ji Park, et al.
Works count: 43
Citation count: 1,086
H-index: 7
I10-index: 7
Year
Topic
Type